Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Gatzemeier

Showing results (1-10 of 52) with videos related to

Pageof 6
Sort By:
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Hypoxic active drugsUlrich Gatzemeier
Oncology (Williston Park, N.Y.)|January 20, 2005
Pemetrexed in malignant pleural mesotheliomaUlrich Gatzemeier
Oncology (Williston Park, N.Y.)|December 20, 2003
Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancerUlrich Gatzemeier
Respiratory Medicine|March 1, 2005
Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancerMartin Reck, Ulrich Gatzemeier
Lung Cancer (Amsterdam, Netherlands)|November 24, 2004
Chemotherapy in stage-IV NSCLCMartin Reck, Ulrich Gatzemeier
Nature Reviews. Clinical Oncology|March 2, 2010
Targeted therapies: Thalidomide in lung cancer therapy-what have we learned?Martin Reck, Ulrich Gatzemeier
Lung Cancer (Amsterdam, Netherlands)|June 30, 2005
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinibMartin Reck, Ulrich Gatzemeier
Expert Review of Anticancer Therapy|May 10, 2005
Pemetrexed-cisplatin combination in mesotheliomaMartin Reck, Ulrich Gatzemeier
Onkologie|December 7, 2005
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatientsMartin Reck, Ulrich Gatzemeier
Seminars in Oncology|May 23, 2002
Phase I trials of pemetrexedFrank V Fossella, Ulrich Gatzemeier
Pageof 6

Showing results (1-10 of 52) with videos related to

Sort By:
Pageof 6
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Hypoxic active drugsUlrich Gatzemeier
Oncology (Williston Park, N.Y.)|January 20, 2005
Pemetrexed in malignant pleural mesotheliomaUlrich Gatzemeier
Oncology (Williston Park, N.Y.)|December 20, 2003
Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancerUlrich Gatzemeier
Respiratory Medicine|March 1, 2005
Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancerMartin Reck, Ulrich Gatzemeier
Lung Cancer (Amsterdam, Netherlands)|November 24, 2004
Chemotherapy in stage-IV NSCLCMartin Reck, Ulrich Gatzemeier
Nature Reviews. Clinical Oncology|March 2, 2010
Targeted therapies: Thalidomide in lung cancer therapy-what have we learned?Martin Reck, Ulrich Gatzemeier
Lung Cancer (Amsterdam, Netherlands)|June 30, 2005
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinibMartin Reck, Ulrich Gatzemeier
Expert Review of Anticancer Therapy|May 10, 2005
Pemetrexed-cisplatin combination in mesotheliomaMartin Reck, Ulrich Gatzemeier
Onkologie|December 7, 2005
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatientsMartin Reck, Ulrich Gatzemeier
Seminars in Oncology|May 23, 2002
Phase I trials of pemetrexedFrank V Fossella, Ulrich Gatzemeier
Pageof 6